Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Codexis is a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover and develop novel, high performance enzymes for three healthcare industry pillars: pharmaceutical manufacturing, life sciences, and biotherapeutic discovery & development. The enzymes we produce aim to solve real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and - as biotherapeutic candidates - they have the potential to treat challenging diseases. To meet this goal, we look for individuals who are driven, eager to grow and ready to embrace meaningful challenges. We empower employees to be authentic, ambitious, agile and have the courage to take action where they can make a positive impact. Whether you are driven by science, or a different area of expertise, we need you to help us create a brighter future.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
76 articles about Codexis, Inc.
-
Codexis to Report Third Quarter 2022 Financial Results on November 3
10/20/2022
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on Thursday, November 3, 2022, following the close of market.
-
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
10/3/2022
Codexis, Inc. today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors.
-
Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
10/3/2022
Codexis, Inc. today announced the appointment of Kevin Norrett as Chief Operating Officer (COO), effective immediately.
-
Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field
9/14/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the recent hosting of its in-person Protein Engineering Forum from September 12-13, 2022 in San Francisco, California.
-
Codexis Reports Second Quarter 2022 Financial Results
8/4/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis
8/2/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announced the execution of a Commercial License and Enzyme Supply Agreement, enabling Molecular Assemblies to utilize an evolved terminal deoxynucleotidyl transferase enzyme in Molecular Assemblies’ Fully Enzymatic Synthesis™ technology.
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers. -
Codexis Announces CEO Transition Effective August 9, 2022
7/18/2022
Codexis, Inc. announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company’s President and CEO, effective August 9, 2022.
-
Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance
7/14/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced preliminary revenue results for the second quarter ending June 30, 2022 and updated its revenue guidance for 2022.
-
Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
7/14/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient (API) in PAXLOVID™.
-
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
6/17/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the peer-reviewed journal Science, detailing the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.
-
Codexis to Participate in Upcoming Healthcare Conferences
5/25/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming investor conferences.
-
Codexis to Participate in Upcoming Healthcare Conferences - May 17, 2022
5/17/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in two upcoming investor conferences.
-
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
5/16/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that three of its gene therapy programs are the subject of two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place from May 16 to May 19, 2022, in Washington, D.C. and virtually.
-
Codexis Reports First Quarter 2022 Financial Results
5/5/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the first quarter ended March 31, 2022, and provided a business update.
-
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
5/2/2022
Codexis, Inc. announced two poster presentations highlighting three of the Company’s gene therapy programs using directed evolution to potentially improve treatment options for Hemophilia A and lysosomal storage diseases at the American Society of Gene and Cell Therapy 25th Annual Meeting, taking place from May 16 to May 19, 2022, in Washington, D.C. and virtually.
-
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
4/21/2022
Codexis, Inc. and seqWell, Inc. announced the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell’s genomics workflow solutions.
-
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
4/12/2022
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced an update on their partnership to engineer enzymes to deliver differentiated solutions for the enzymatic synthesis of DNA.
-
Codexis to Participate in the Cowen 42nd Annual Health Care Conference
3/1/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42nd Annual Health Care Conference, being held virtually March 7-9, 2022.
-
Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results
2/24/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update.